| Literature DB >> 24669875 |
Dong Jin Kim, Jun Hyun Lee, Wook Kim1.
Abstract
BACKGROUND: Minimally invasive surgery has been slowly introduced into the field of advanced gastric cancer (AGC) surgery. However, the appropriate extent of omentectomy during laparoscopic gastrectomy for AGC is unknown.Entities:
Mesh:
Year: 2014 PMID: 24669875 PMCID: PMC3986882 DOI: 10.1186/1477-7819-12-64
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
The clinicopathologic features of patients with serosa-negative advanced gastric cancer (AGC) according to the type of omentectomy
| Age (years)a | | 60.9 ± 11.2 | 62.2 ± 11.0 | 0.483 |
| Sex | Male | 56 (70) | 50 (75.8) | 0.438 |
| Female | 24 (30) | 16 (24.2) | | |
| Extent of resection | Total | 19 (23.8) | 12 (18.2) | 0.413 |
| Distal | 61 (76.3) | 54 (81.8) | | |
| Depth of invasion | pT2 | 28 (35) | 37 (56.1) | 0.011 |
| pT3 | 52 (65) | 29 (43.9) | | |
| Lymph node metastasis | 0 | 40 (50) | 34 (51.5) | 0.419 |
| 1 | 14 (17.5) | 8 (12.1) | | |
| 2 | 13 (16.3) | 16 (24.2) | | |
| 3a | 6 (7.5) | 6 (9.1) | | |
| 3b | 7 (8.8) | 2 (3.0) | | |
| Tumor stage (UICC 7th) | Ib | 17 (21.3) | 23 (34.8) | 0.130 |
| IIa | 30 (37.5) | 15 (22.7) | | |
| IIb | 9 (11.3) | 11 (16.7) | | |
| IIIa | 13 (16.3) | 12 (18.2) | | |
| IIIb | 11 (13.8) | 5 (7.6) | | |
| Tumor size (cm)a | | 4.8 ± 2.5 | 4.4 ± 2.4 | 0.366 |
| Histologic type | Differentiated | 37 (46.3) | 24 (36.4) | 0.228 |
| Undifferentiated | 43 (53.8) | 42 (63.6) | | |
| Proximal margin (cm)a | | 4.0 ± 2.1 | 3.7 ± 2.2 | 0.357 |
| Distal margin (cm)a | | 5.3 ± 3.4 | 6.4 ± 4.2 | 0.083 |
| Lymphatic invasion | Absent | 27 (33.8) | 30 (45.5) | 0.149 |
| Present | 53 (66.3) | 36 (54.5) | | |
| Perineural invasion | Absent | 39 (48.8) | 40 (60.6) | 0.152 |
| Present | 42 (51.3) | 26 (39.4) | ||
aMean ± standard deviation; nominal variables are expressed as number (%).
Surgical outcomes in patients with serosa-negative advanced gastric cancer (AGC) according to the type of omentectomy
| Lymph node (LN) dissection | D1 + β | 2 (2.5) | 6 (7.6) | 0.153 |
| | D2 | 78 (97.5) | 61 (92.4) | |
| Number of retrieved LNsa | | 34.6 ± 14.7 | 39.8 ± 14.7 | 0.034 |
| Number of metastatic LNsa | | 4.3 ± 8.5 | 2.9 ± 5.3 | 0.228 |
| Omentectomy time (min)a | | 50.9 ± 15.5 | 35.1 ± 13.0 | %0.001 |
| Omentectomy-related complication | | 2b | 0 | 0.198 |
| Recurrence | 14 (17.5) | 5 (7.6) | 0.076 | |
aMean ± standard deviation; nominal variables are expressed as number (%).
Complications included intra-operative spleen and mesocolon injury, requiring concurrent splenectomy and transverse colectomy.
Recurrence pattern according to the type of omentectomy and the depth of invasion
| pT2 (65) | Total omentectomy (28) | 2 | 3rd-tier lymph node (LN) (1) |
| Bone (1) | |||
| | Partial omentectomy (37) | 2 | 3rd-tier LN + bone (1) |
| Remnant stomach (1) | |||
| pT3 (81) | Total omentectomy (52) | 12 | Carcinomatosis (3)a |
| Liver (3) | |||
| Bone (1) | |||
| 3rd-tier lymph node (2) | |||
| Remnant stomach (3) | |||
| Partial omentectomy (29) | 3 | Carcinomatosis (1)a | |
| Liver (1) | |||
| Port site (1) |
aProportion of carcinomatosis in total omentectomy versus partial omentectomy: 3/80 (3.8%) versus 1/66 (1.5%), P = 0.410 (chi-square analysis).
Figure 1Survival analysis. (A) Disease-free survival did not differ between the total omentectomy (TO) and the partial omentectomy (PO) groups. (B) Disease-specific overall survival did not differ between the total omentectomy and the partial omentectomy groups. (C) Disease-free survival did not differ between the matched groups.
Univariate and multivariate analyses of the risk factors for recurrence
| Type of omentectomy | Total | 81.5 | 0.42 | 1 | 0.766 |
| | Partial | 89.3 | | 0.85 (0.30 to 2.43) | |
| Depth of invasion | pT2 | 92.5 | 0.015 | 1 | 0.082 |
| | pT3 | 77.5 | | 3.00 (0.87 to 10.39) | |
| Lymph node metastasis | Absent | 97.2 | %0.001 | 1 | 0.003 |
| Present | 68.5 | 9.98 (2.06 to 39.14) | |||
aDisease-free survival.
Proportions of T-stage and N-stage in matched groups
| Depth of invasion | pT2 | 22 (43.1) | 22 (43.1) | 1.000 |
| pT3 | 29 (56.9) | 29 (43.9) | | |
| Lymph node metastasis | 0 | 28 (54.9) | 28 (54.9) | 1.000 |
| 1 | 8 (15.7) | 8 (15.7) | | |
| 2 | 11 (21.6) | 11 (21.6) | | |
| 3a | 2 (3.9) | 2 (3.9) | | |
| 3b | 2 (3.9) | 2 (3.9) | ||